- Rekrutierung läuft
A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma
- Rekrutierung läuftA Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects with Advanced Solid TumorsAMG 994, AMG 404
- Rekrutierung läuft
A Randomized, Open-label, Controlled Phase 3 Adaptive Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With High-risk First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen Protocol Number 20120215 (ALL-Rez HR Rando HC3 vs Blin)
Molekulare Marker - Rekrutierung läuft
A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma
Indikationen - Rekrutierung läuft
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (PAVO)
Molekulare Marker - Rekrutierung läuftA Phase 1/2, Multicenter, Open-Label Study to Assess Safety, Pharmacokinetics, and preliminary efficacy of CC-220, alone and in combination with an anti-CD20 Monoclonal Antibody (MAB) in subjects with relapsed or refractory LymphomasMolekulare Marker
- Rekrutierung läuftA phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)Molekulare Marker
- Rekrutierung läuftA Prospective, Open-Label, Multicenter Phase-2-Trial to Evaluate the Efficacy and Safety of Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients with Relapsed/Refractory CLLMolekulare Marker
- Rekrutierung läuftA prospective, randomized, open-label, multicenter, phase 2 Trial to evaluate the safety and efficacy of the combination of GS-4059 and Idelalisib with and without Obinutuzumab in subjects with chronic lymphocytic leukemia.Molekulare Marker
- Rekrutierung läuftA Phase I, first-in-human, dose escalation study of MGD006, a CD123 x CD3 dual affinity re-targeting (DART) bi-specific antibody-based molecule, in patients with relapsed or refractory acute myeloid leukemia or intermediate-2/high risk myelodysplastic syndromIndikationenMolekulare Marker